ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.67
0.00%
US Tech 100
19,214.80
0.00%
S&P 500
5,477.90
0.16%
US Dollar vs CAD
1.3689
-0.12%
Bitcoin
60,737.26
-0.12%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AnaptysBio Inc (ANAB) Share Price

AnaptysBio Inc

AnaptysBio Inc (ANAB)

NASDAQ
24.22
0.00
(0.00%)
Closed June 27 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
24.22
Bid
23.25
Ask
33.49
Volume
-
0.00 Day's Range 0.00
13.36 52 Week Range 27.50
Market Cap
661.931M
Previous Close
24.22
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
356,352
Shares Outstanding
27,318,644
Dividend Yield
-
PE Ratio
-4.05
Earnings Per Share (EPS)
-5.99
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.anaptysbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was US$24.22. Over the last year, AnaptysBio shares have traded in a share price range of US$ 13.36 to US$ 27.50.

AnaptysBio currently has 27,318,644 shares outstanding. The market capitalization of AnaptysBio is US$661.93 million. AnaptysBio has a price to earnings ratio (PE ratio) of -4.05.

ANAB Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 12 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 09 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 09 2024
Edgar (US Regulatory)
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
11.255.4418807139722.9724.616722.2648311223.80609806CS
40.552.3236163920623.6725.042322.2635220923.77690016CS
123.416.33045148920.8227.0218.4935635223.37701383CS
262.7212.651162790721.527.518.4932933123.38026406CS
523.9319.369147363220.2927.513.3628970321.14404556CS
156-2.37-8.9131252350526.5937.8913.3625148223.6244196CS
260-29.86-55.214497041454.0857.829.1633038322.24944442CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DNDelta 9 Cannabis Inc
$ 0.015
(50.00%)
411.77k
SCYScandium International Mining Corp
$ 0.02
(33.33%)
12k
FANSFansUnite Entertainment Inc
$ 0.045
(28.57%)
642.14k
THTheratechnologies Inc
$ 2.14
(20.22%)
77.34k
BCTBriaCell Therapeutics Corp
$ 1.53
(17.69%)
13.66k
NCFNorthcliff Resources Ltd
$ 0.02
(-20.00%)
39k
AMMAlmaden Minerals Ltd New
$ 0.085
(-19.05%)
3.24k
IVQInvesque Inc
$ 0.145
(-14.71%)
101.2k
LPENLoop Energy Inc
$ 0.03
(-14.29%)
55k
ASNDAscendant Resources Inc
$ 0.035
(-12.50%)
11k
TRPTC Energy Corporation
$ 52.80
(-1.31%)
13.61M
CNQCanadian Natural Resources Ltd
$ 48.35
(-0.04%)
11.93M
POWPower Corp of Canada
$ 38.32
(0.31%)
6.58M
FCUFission Uranium Corp
$ 1.18
(-0.84%)
5.61M
VGCXVictoria Gold Corp
$ 1.28
(-5.88%)
5.23M

ANAB Discussion

View Posts
gfp927z gfp927z 2 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 2 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 2 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 2 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 4 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 5 years ago
$10 to da moon
👍️0
420man 420man 5 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 5 years ago
Ouch -
👍️0
celle celle 5 years ago
Nothing happen here?
👍️0
manny371 manny371 6 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

NASDAQ
ANAB
AnaptysBio
NASDAQ
WAVD
WaveDancer
TG
01DS
BlackRock Institutional ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved